BPC-157 + KPV + Larazotide Gut Healing Stack

The gut healing stack combines three peptides targeting distinct aspects of intestinal repair: BPC-157 for mucosal healing and angiogenesis, KPV for intestinal inflammation suppression, and larazotide acetate for tight junction restoration. Together, they address the three core pathologies of gut dysfunction — mucosal damage, chronic inflammation, and intestinal permeability (colloquially 'leaky gut').

Quick Comparison

Property	peptide	The Gut Healing Stack: BPC-157 + KPV + Larazotide
Source	Salmon DNA fragments	Various sources
Primary Mechanism	A2A receptor activation, DNA repair	Varies by ingredient
Key Benefits	Tissue regeneration, anti-inflammation, collagen boost	Multiple skin benefits
Best Time to Apply	AM or PM	AM or PM
Can Combine?	Generally compatible — check specific guidelines.

How to Use Together

BPC-157: 250-500 mcg twice daily, administered orally (stable in gastric acid, unlike most peptides) or subcutaneously. Oral administration is preferred for GI-targeted effects as it delivers the peptide directly to the intestinal mucosa. KPV: 200-500 mcg daily, administered orally or subcutaneously. For localized intestinal effect, oral capsule delivery targeting ileal release is theoretically optimal. Larazotide acetate: 0.5-1 mg three times daily before meals, administered orally (this is its intended route — it acts locally in the intestinal lumen without systemic absorption).

Cycle: 4-8 weeks on, 4 weeks off. Some users run BPC-157 continuously for gut maintenance at lower doses (250 mcg/day) while cycling the other two components. Take larazotide 15-30 minutes before meals for optimal tight junction modulation during food antigen exposure.

Safety Notes

BPC-157 has no reported serious adverse effects in the available literature, though human clinical trial data is limited. Its pro-angiogenic mechanism raises theoretical concern in individuals with existing cancers, as new blood vessel formation could support tumor growth. KPV is a fragment of alpha-MSH and is generally well-tolerated; the main concern is potential melanogenesis stimulation at high doses, though this has not been clinically observed with the tripeptide fragment. Larazotide acetate has the most human safety data of the three — it has been through Phase 2 and Phase 3 clinical trials for celiac disease with a favorable safety profile. The combination has never been formally tested for drug interactions. Consult a gastroenterologist before beginning any gut peptide protocol, particularly if you have IBD, celiac disease, or are on immunosuppressive medications.

Recommended Products (3)

All Products →

healing body-protection

BPC-157

Research-Grade

A 15-amino-acid peptide fragment derived from gastric juice protein BPC, studied extensively in animal models for tissue healing and gut integrity.

immune modulator

KPV

Research-Grade

A C-terminal tripeptide fragment of alpha-MSH with potent anti-inflammatory activity, studied for its role in modulating NF-κB signaling without melanogenic effects.

healing body-protection

Larazotide Acetate

Pharmaceutical

A synthetic octapeptide tight junction regulator studied in Phase III clinical trials for celiac disease — acts locally in the gut to prevent paracellular permeability increase (leaky gut).

BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from human gastric juice that has demonstrated robust gastrointestinal healing activity in dozens of animal studies. It promotes angiogenesis (new blood vessel formation) in damaged tissue, accelerates mucosal repair, and modulates nitric oxide pathways critical for gut motility and blood flow. KPV is a tripeptide (Lys-Pro-Val) derived from alpha-MSH that suppresses NF-kB-mediated intestinal inflammation — the same inflammatory cascade implicated in IBD, IBS, and post-infectious gut dysfunction. Larazotide acetate is a synthetic peptide that acts as a tight junction regulator, directly closing the paracellular spaces between enterocytes that become pathologically widened in intestinal permeability disorders.

This three-peptide combination is mechanistically coherent because each targets a different layer of gut pathology: BPC-157 repairs the damaged tissue, KPV suppresses the inflammation that caused the damage, and larazotide restores the barrier function that prevents further antigen translocation and immune activation. The theoretical synergy is strong, though no clinical trial has tested this specific combination in humans.

Frequently Asked Questions

Can I take BPC-157 orally for gut healing, or must it be injected?

BPC-157 is one of the rare peptides that is stable in gastric acid and retains bioactivity when administered orally. For gut-specific healing, oral administration is actually preferred over injection because it delivers the peptide directly to the intestinal mucosa where it acts. Subcutaneous injection provides systemic BPC-157 levels that also reach the gut via circulation, but oral delivery achieves higher local concentrations in the GI tract.

How long does it take to notice gut healing improvements?

Symptom improvement timelines vary by condition severity. Mild intestinal permeability and post-antibiotic gut issues often show improvement within 2-4 weeks. IBD-related mucosal damage and chronic inflammatory conditions may require 6-12 weeks for noticeable improvement. Larazotide's tight junction effects begin within hours of administration, but the clinical benefit accumulates over weeks of consistent use.

Is this stack appropriate for IBS?

It depends on the IBS subtype and underlying mechanism. For IBS with confirmed intestinal permeability (measurable by lactulose-mannitol test), this stack directly addresses the pathology. For IBS-D with post-infectious origins, BPC-157 and KPV may address residual mucosal inflammation. For purely motility-driven IBS without permeability or inflammatory components, this stack may be less relevant.

Can I use this alongside conventional IBD medications?

There is no published interaction data between these peptides and standard IBD medications (mesalamine, biologics, immunomodulators). Theoretically, KPV's anti-inflammatory mechanism (NF-kB suppression) operates on the same pathway as some IBD drugs, which could produce additive or redundant effects. Discuss with your gastroenterologist before combining — do not discontinue prescribed IBD medications in favor of peptides.

Should I take all three peptides simultaneously or introduce them one at a time?

Introducing one at a time over 2-3 weeks allows you to assess individual tolerance and identify which peptide produces the most noticeable benefit. A common introduction order: larazotide first (most human safety data), then BPC-157 (oral, well-tolerated), then KPV. Once all three are tolerated individually, combining them for the full 4-8 week protocol is reasonable.

What dietary changes should accompany this stack?

Peptide gut healing is most effective alongside dietary support: remove known inflammatory triggers (processed foods, excess alcohol, identified food sensitivities), include prebiotic fiber to support commensal bacteria, and consider a spore-based probiotic. An elimination diet (AIP or low-FODMAP) during the first 4 weeks of the stack can reduce the antigenic load on the healing gut and amplify the peptides' effects.

Other peptide Ingredient Combinations

The Anti-Aging Stack: GHK-Cu + Epitalon

GHK-Cu and Epitalon target two distinct hallmarks of aging — extracellular matrix degradation and te…

The Athletic Performance Stack: IGF-1 LR3 + Ipamorelin + BPC-157

The athletic performance stack layers three peptides with distinct but complementary mechanisms to s…

The Cognitive Stack: Semax + Selank

The classic Russian nootropic peptide pairing. Semax (an ACTH 4-10 analog) enhances BDNF expression …

The Fat Loss Stack: Tesamorelin + CJC-1295/Ipamorelin

Tesamorelin and CJC-1295/Ipamorelin both target the GH axis but through complementary timing and rec…

The GH Stack: CJC-1295 + Ipamorelin

The dual-pathway growth-hormone stack. CJC-1295 (GHRH analog) opens the pituitary somatotroph; Ipamo…

The Healing Stack: BPC-157 + TB-500

The canonical regenerative-peptide pairing. BPC-157 and TB-500 operate through non-overlapping biolo…

Immune Support Stack

A combination approach targeting immune function through three complementary mechanisms: adaptive im…

The Joint Repair Stack: BPC-157 + Pentosan Polysulfate + TB-500

A comprehensive joint-repair protocol targeting all layers of joint pathology: BPC-157 for periartic…

The Longevity Stack: Epitalon + MOTS-c + SS-31

Three peptides targeting different hallmarks of aging: Epitalon for telomerase activation and pineal…

The Metabolic Stack: GLP-1 + GHS

A newer 'metabolic recomposition' pairing some practitioners use: a GLP-1 agonist for appetite and t…

The Nootropic Stack: Semax + Selank + GH-Axis Support

A three-tier nootropic peptide stack targeting cognitive performance through complementary mechanism…

The Sexual Health Stack: PT-141 + Kisspeptin-10

PT-141 and Kisspeptin-10 target complementary aspects of sexual function — central desire pathways a…

The Skin Rejuvenation Stack: GHK-Cu + GH-Axis + Collagen

A multi-level skin rejuvenation protocol combining topical signaling (GHK-Cu), systemic GH-axis elev…

The Sleep Stack: DSIP + Ipamorelin

DSIP (Delta Sleep-Inducing Peptide) and ipamorelin target complementary aspects of sleep optimizatio…

The Weight Loss Stack: Semaglutide/Tirzepatide + Tesamorelin

This weight loss stack combines GLP-1 receptor agonist therapy (semaglutide or tirzepatide) with the…

Browse All peptide Products